Needham analyst Joseph Stringer maintained a Buy rating on Vir Biotechnology today and set a price target of $18.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Stringer has given his Buy rating due to a combination of factors, primarily the strengthening competitive position of Vir Biotechnology’s HDV program relative to key rivals. He notes that recent Phase 2b data from Mirum’s brelovitug trial, while technically successful, showed lower composite response rates than earlier brelovitug studies and underperformed Vir’s elebsiran plus tobevibart regimen at comparable 24-week time points.
He also emphasizes that on a stricter virologic measure, the “target not detected” rate, Mirum’s results lag Vir’s Phase 2 outcomes, reinforcing his view that Vir’s combination has a best‑in‑class efficacy and dosing profile. With an HDV market opportunity he estimates at roughly $1.5–2 billion and pivotal Phase 3 data expected to begin readouts in 4Q26, Stringer sees Vir well positioned to capture meaningful share, supporting his unchanged $18 price target and Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $30.00 price target.